New injection targets tumors directly in advanced cancer trial
NCT ID NCT04260529
First seen Feb 01, 2026 · Last updated May 14, 2026 · Updated 12 times
Summary
This early-phase trial tested an experimental drug called CyPep-1, injected directly into tumors, either alone or with the immunotherapy pembrolizumab. The study included 60 adults with advanced solid cancers that had stopped responding to standard treatments. The main goals were to check safety and see if the drug could shrink injected tumors and even distant tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR MALIGNANCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
EMC
Rotterdam, Netherlands
-
Institue Curie
Paris, France
-
Institute Gustave Roussy
Villejuif, France
-
LUMC
Leiden, Netherlands
-
NKI/AvL
Amsterdam, Netherlands
-
START
Madrid, Spain
-
UMCU
Utrecht, Netherlands
-
Vall d'Hebron (VHIO)
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.